GENE THERAPY FOR BRAIN TUMORS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。恶性胶质瘤是最难治疗的脑肿瘤之一。单纯疱疹病毒（HSV）载体正在测试选择性地向肿瘤细胞递送药物增强基因。本项目的目的是研究免疫机制对单纯疱疹病毒介导的肿瘤溶解的贡献。对HSV载体的免疫反应及其对肿瘤消退的影响正在普通狨猴中进行评估。假设T淋巴细胞对HSV载体的细胞溶解选择性靶向肿瘤细胞将增强病毒诱导的溶瘤作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Malignant gliomas constitute one of the brain tumors that are most refractory to treatment. Herpes simplex virus (HSV) vectors are being tested for selective delivery of drug-enhancing genes to tumor cells. The goal of this project is to investigate the contribution of immune mechanisms to HSV-mediated oncolysis. Immune responses to HSV vectors and their effect on tumor regression are being evaluated in common marmoset monkeys. It is hypothesized that cytolytic T lymphocytes to HSV vectors selectively targeting tumor cells will enhance virus-induced oncolysis.